Phase 2
N=15
Effect of Lorcaserin on Cannabis Withdrawal and Self-administration
Cannabis Use
Bottom Line
View on ClinicalTrials.gov: NCT03253926 ↗Enrolled (actual)
15
Serious AEs
0.0%
Results posted
Jul 2022
Primary outcome: Primary: Cannabis Self-administration — 5.75; 9.2; 5.75; 7.5 puffs of cannabis chosen
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Lorcaserin (Drug); Placebo (Drug); Marijuana (Drug)
- Age
- Adult · 21+ yrs
- Sex
- All
- Sponsor
- New York State Psychiatric Institute
- Primary completion
- May 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cannabis Self-administration |
5.75; 9.2; 5.75; 7.5 | — |
Summary
In this study, the investigators are interested in testing how lorcaserin influences the effects of cannabis in a human laboratory model of cannabis use.
Eligibility Criteria
Inclusion Criteria
- Current cannabis use
- Able to give informed consent and perform study procedures
- Women practicing an effective form of birth control
- English speaking
Exclusion Criteria
- Presence of any clinically significant medical diagnoses
- History of heart disease and cardiac risk factors, severe chronic obstructive pulmonary disease, uncontrolled hypertension, or diabetes
- Current parole or probation
- Certain psychiatric diagnoses
- Current pregnancy or lactation
Data sourced from ClinicalTrials.gov (NCT03253926). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.